Benjamin L. Oakes
@benjaminloakes.bsky.social
CEO @ Scribetx.com | at the interface of molecular and genetic engineering | designing CRISPR to be safe enough for all
Reposted by Benjamin L. Oakes
“In reality, you’re seeing nothing but good data come out of the CRISPR space. I don’t believe the ability to cure patients is going anywhere.” – @benjaminloakes.bsky.social, Scribe CEO in GEN on delivering the full promise of #CRISPR
Read more here and our 🧵: www.genengnews.com/topics/genom...
Read more here and our 🧵: www.genengnews.com/topics/genom...
Advancing CRISPR Cures Requires Cross-Sector Collaboration
Amid a challenging gene editing climate, partnerships between researchers, regulators, and industry remain crucial for pushing CRISPR cures to the clinic.
www.genengnews.com
June 20, 2025 at 4:04 PM
“In reality, you’re seeing nothing but good data come out of the CRISPR space. I don’t believe the ability to cure patients is going anywhere.” – @benjaminloakes.bsky.social, Scribe CEO in GEN on delivering the full promise of #CRISPR
Read more here and our 🧵: www.genengnews.com/topics/genom...
Read more here and our 🧵: www.genengnews.com/topics/genom...
Reposted by Benjamin L. Oakes
We’re pleased to announce the achievement of a success milestone in our collaboration with Prevail Therapeutics, a part of @elilillyandcompany.bsky.social’s Gene Therapy Division, to develop in vivo #CRISPR-based therapeutics for neurological and neuromuscular disorders.
Highlights below 🧵
Highlights below 🧵
April 28, 2025 at 6:53 PM
We’re pleased to announce the achievement of a success milestone in our collaboration with Prevail Therapeutics, a part of @elilillyandcompany.bsky.social’s Gene Therapy Division, to develop in vivo #CRISPR-based therapeutics for neurological and neuromuscular disorders.
Highlights below 🧵
Highlights below 🧵
The future of medicine is bright — and it’s going to look radically different from today.
It’ll be:
🧬 Preventive
⚡ Liberating
🌍 Universal
This isn’t science fiction — it’s what we’re building at @ScribeRx. Let me break it down 👇
It’ll be:
🧬 Preventive
⚡ Liberating
🌍 Universal
This isn’t science fiction — it’s what we’re building at @ScribeRx. Let me break it down 👇
This #WorldHealthDay, join us in building a future of a healthier life for all.
At Scribe, we're engineering #CRISPR-based therapies designed to transform everyone's lifetime risk for disease.
Learn more about causes for World Health Day from @who.int: www.who.int/campaigns/wo...
At Scribe, we're engineering #CRISPR-based therapies designed to transform everyone's lifetime risk for disease.
Learn more about causes for World Health Day from @who.int: www.who.int/campaigns/wo...
April 7, 2025 at 11:02 PM
The future of medicine is bright — and it’s going to look radically different from today.
It’ll be:
🧬 Preventive
⚡ Liberating
🌍 Universal
This isn’t science fiction — it’s what we’re building at @ScribeRx. Let me break it down 👇
It’ll be:
🧬 Preventive
⚡ Liberating
🌍 Universal
This isn’t science fiction — it’s what we’re building at @ScribeRx. Let me break it down 👇
Reposted by Benjamin L. Oakes
#LpaAwarenessDay
Cardiovascular disease is the leading cause of death worldwide, claiming 18 million lives each year.
Did you know that 1 in 5 people have high levels of Lp(a) or lipoprotein(a), which significantly increases the risk of heart disease?
Cardiovascular disease is the leading cause of death worldwide, claiming 18 million lives each year.
Did you know that 1 in 5 people have high levels of Lp(a) or lipoprotein(a), which significantly increases the risk of heart disease?
March 24, 2025 at 8:43 PM
#LpaAwarenessDay
Cardiovascular disease is the leading cause of death worldwide, claiming 18 million lives each year.
Did you know that 1 in 5 people have high levels of Lp(a) or lipoprotein(a), which significantly increases the risk of heart disease?
Cardiovascular disease is the leading cause of death worldwide, claiming 18 million lives each year.
Did you know that 1 in 5 people have high levels of Lp(a) or lipoprotein(a), which significantly increases the risk of heart disease?
This week, I’ll highlight two recent CRISPR advances: 1) BEAM’s exciting Phase 1 clinical data for BEAM-302. 2) Impressive work from the labs of Scribe’s co-founders @savagecatsonly.bsky.social & @doudna-lab.bsky.social —providing a textbook example of engineering CRISPR enzymes from zero to hero.
March 21, 2025 at 8:19 PM
This week, I’ll highlight two recent CRISPR advances: 1) BEAM’s exciting Phase 1 clinical data for BEAM-302. 2) Impressive work from the labs of Scribe’s co-founders @savagecatsonly.bsky.social & @doudna-lab.bsky.social —providing a textbook example of engineering CRISPR enzymes from zero to hero.
Reposted by Benjamin L. Oakes
From an interview with our CEO @benjaminloakes.bsky.social, PharmaVoice spotlighted our work engineering #CRISPR genome editing and epigenetic silencing platforms to target cardiometabolic disease.
Read the story about our lead asset and progress: www.pharmavoice.com/news/crispr-...
Read the story about our lead asset and progress: www.pharmavoice.com/news/crispr-...
CRISPR’s cardio catch-all drives a biotech’s broad potential
Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.
www.pharmavoice.com
March 20, 2025 at 5:00 PM
From an interview with our CEO @benjaminloakes.bsky.social, PharmaVoice spotlighted our work engineering #CRISPR genome editing and epigenetic silencing platforms to target cardiometabolic disease.
Read the story about our lead asset and progress: www.pharmavoice.com/news/crispr-...
Read the story about our lead asset and progress: www.pharmavoice.com/news/crispr-...
Reposted by Benjamin L. Oakes
Don’t miss @jdfev.bsky.social's late-breaking talk at @keystonesymposia.bsky.social today!
📣 Symposia Spotlight
🪧 Engineering of Next Generation Epigenetic Editors for Enhanced Durable Repression in Non-Human Primates
🕒 3:00-4:30 p.m. GMT
📍 INEC Main Auditorium
📣 Symposia Spotlight
🪧 Engineering of Next Generation Epigenetic Editors for Enhanced Durable Repression in Non-Human Primates
🕒 3:00-4:30 p.m. GMT
📍 INEC Main Auditorium
March 4, 2025 at 12:00 PM
Don’t miss @jdfev.bsky.social's late-breaking talk at @keystonesymposia.bsky.social today!
📣 Symposia Spotlight
🪧 Engineering of Next Generation Epigenetic Editors for Enhanced Durable Repression in Non-Human Primates
🕒 3:00-4:30 p.m. GMT
📍 INEC Main Auditorium
📣 Symposia Spotlight
🪧 Engineering of Next Generation Epigenetic Editors for Enhanced Durable Repression in Non-Human Primates
🕒 3:00-4:30 p.m. GMT
📍 INEC Main Auditorium
🧬 In the near future, my hope is that we can all win the genetic lottery for health—not by chance, but by design. At Scribe, we’re focused on making genetic medicines safe enough for disease prevention at scale and moving beyond gene editing into epigenetic editing.
#CRISPR can change the world—without editing your DNA. A new @economist.com report highlights epigenetic editing as a transformative technology and our work at Scribe engineering epigenetic editors (ELXRs) as genetic medicines potent and safe enough for broad patient populations.
March 4, 2025 at 12:26 AM
🧬 In the near future, my hope is that we can all win the genetic lottery for health—not by chance, but by design. At Scribe, we’re focused on making genetic medicines safe enough for disease prevention at scale and moving beyond gene editing into epigenetic editing.
As someone with close family affected by ASCVD—and therefore at high risk myself—this mission is personal, urgent and real. We will solve this.
Explore our vision for the future of ASCVD treatment—and, more importantly, prevention—below.
Explore our vision for the future of ASCVD treatment—and, more importantly, prevention—below.
Did you know that elevated LDL-C can increase risk for cardiovascular disease, the leading cause of death worldwide?
As we observe #HeartMonth, we’re reminded of the importance of heart health and the ongoing fight against cardiometabolic disease ⬇️
As we observe #HeartMonth, we’re reminded of the importance of heart health and the ongoing fight against cardiometabolic disease ⬇️
March 1, 2025 at 1:14 AM
As someone with close family affected by ASCVD—and therefore at high risk myself—this mission is personal, urgent and real. We will solve this.
Explore our vision for the future of ASCVD treatment—and, more importantly, prevention—below.
Explore our vision for the future of ASCVD treatment—and, more importantly, prevention—below.
As someone with close family affected by ASCVD—and therefore at high risk myself—this mission is personal, urgent and real. We will solve this.
Explore our vision for the future of ASCVD treatment—and, more importantly, prevention—below.
Explore our vision for the future of ASCVD treatment—and, more importantly, prevention—below.
Did you know that elevated LDL-C can increase risk for cardiovascular disease, the leading cause of death worldwide?
As we observe #HeartMonth, we’re reminded of the importance of heart health and the ongoing fight against cardiometabolic disease ⬇️
As we observe #HeartMonth, we’re reminded of the importance of heart health and the ongoing fight against cardiometabolic disease ⬇️
March 1, 2025 at 12:45 AM
As someone with close family affected by ASCVD—and therefore at high risk myself—this mission is personal, urgent and real. We will solve this.
Explore our vision for the future of ASCVD treatment—and, more importantly, prevention—below.
Explore our vision for the future of ASCVD treatment—and, more importantly, prevention—below.
Trying something new—highlighting research that I find enjoyable or useful in CRISPR, molecular engineering, and cardiometabolic disease.
To kick things off, here are two new papers: A clever single-cell off-target method and an exploration of how Prime Editors modify global DNA repair
To kick things off, here are two new papers: A clever single-cell off-target method and an exploration of how Prime Editors modify global DNA repair
February 27, 2025 at 6:57 PM
Trying something new—highlighting research that I find enjoyable or useful in CRISPR, molecular engineering, and cardiometabolic disease.
To kick things off, here are two new papers: A clever single-cell off-target method and an exploration of how Prime Editors modify global DNA repair
To kick things off, here are two new papers: A clever single-cell off-target method and an exploration of how Prime Editors modify global DNA repair
Check it out—we gave our website a fresh new look! 🔥
Like our CRISPR by Design™ approach, this redesign is all about precision and continuous improvement. Whether pushing the boundaries of genetic medicine or refining how we share our work, one thing never changes: at Scribe, the details matter.
Like our CRISPR by Design™ approach, this redesign is all about precision and continuous improvement. Whether pushing the boundaries of genetic medicine or refining how we share our work, one thing never changes: at Scribe, the details matter.
At Scribe, we’re rewriting the story of disease because genetic predisposition shouldn’t dictate your health destiny. Join us on our mission to build CRISPR-based therapies to transform everyone's lifetime risk for disease. Explore our new website ➡️ scribetx.com
February 25, 2025 at 7:46 PM
Check it out—we gave our website a fresh new look! 🔥
Like our CRISPR by Design™ approach, this redesign is all about precision and continuous improvement. Whether pushing the boundaries of genetic medicine or refining how we share our work, one thing never changes: at Scribe, the details matter.
Like our CRISPR by Design™ approach, this redesign is all about precision and continuous improvement. Whether pushing the boundaries of genetic medicine or refining how we share our work, one thing never changes: at Scribe, the details matter.